Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Important Ordering Details

Custom Ordering Details: When ordering five or more kits, please contact us for processing time and pricing at sales@cellsignal.com.
Friends and Family

25% Off

the purchase of 3 or more products

Shop

Questions?

Find answers on our FAQs page.

ANSWERS  

PhosphoSitePlus® Resource

  • Additional protein information
  • Analytical tools

LEARN MORE

REACTIVITY

Product Description

The PathScan® EGF Receptor (E746-A750del Specific) Sandwich ELISA Kit is a solid phase sandwich enzyme-linked immunosorbent assay (ELISA) that detects endogenous levels of EGF receptor E746-A750del mutant protein. An EGF receptor (E746-A750del Specific) rabbit mAb has been coated on the microwells. After incubation with cell lysates, EGF receptor E746-A750del mutant protein (phospho and nonphospho) is captured by the coated antibody. Following extensive washing, an EGF receptor mouse monoclonal detection antibody is added to detect captured EGF receptor mutant protein. Anti-mouse IgG, HRP-linked antibody is then used to recognize the bound detection antibody. HRP substrate, TMB, is added to develop color. The magnitude of the absorbance for this developed color is proportional to the quantity of EGF receptor E746-A750del mutant protein.

Antibodies in kit are custom formulations specific to kit.


Specificity / Sensitivity

PathScan® EGF Receptor (E746-A750del Specific) Sandwich ELISA Kit #8950 detects endogenous levels of EGF receptor E746-A750del mutant protein in human cells, as shown in Figure 1. The kit sensitivity is shown in Figure 2. This kit detects proteins from the indicated species, as determined through in-house testing, but may also detect homologous proteins from other species.


The epidermal growth factor (EGF) receptor is a 170 kDa transmembrane tyrosine kinase that belongs to the HER/ErbB protein family. Research studies have shown that somatic mutations in the tyrosine kinase domain of EGF receptor (EGFR) are present in a subset of lung adenocarinomas that respond to EGFR inhibitors, such as gefinitib and erlotinib (1-3). Two types of mutations account for approximately 90% of mutated cases: a specific point mutation, L858R, that occurs in exon 21 and short in-frame deletions in exon 19 (4,5). The most frequent exon 19 deletion is E746-A750, accounting for 90% of lesions at this site, although some rare variants occur.


1.  Lynch, T.J. et al. (2004) N Engl J Med 350, 2129-39.

2.  Pao W et al. (2004) Proc Natl Acad Sci U S A 101, 13306–11

3.  Haber, D.A. et al. (2005) Cold Spring Harb Symp Quant Biol 70, 419-26.

4.  Kosaka, T. et al. (2004) Cancer Res 64, 8919-23.

5.  Riely, G.J. et al. (2006) Clin Cancer Res 12, 7232-41.


Entrez-Gene Id 1956
Swiss-Prot Acc. P00533


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
PathScan is a trademark of Cell Signaling Technology, Inc.

8950
PathScan® EGF Receptor (E746-A750del Specific) Sandwich ELISA Kit